Sinopharm (CNCM LTD) Q3 2026: Revenue Reaches RMB 13.88 Billion, Net Profit Advances 9.7%

Bulletin Express10-20

Sinopharm Group Co. Ltd. released unaudited results for its Shanghai-listed subsidiary, China National Medicines Corporation Ltd. (Sinopharm CNCM LTD), covering the three months ended 30 September 2026.

Third-quarter performance • Revenue rose 0.95 % year on year to RMB 13.88 billion. • Net profit attributable to shareholders increased 9.70 % to RMB 0.60 billion, while profit after excluding non-recurring items climbed 10.59 % to RMB 0.60 billion. • Basic and diluted earnings per share (EPS) stood at RMB 0.7906, up 9.71 %. • Weighted average return on equity (ROE) edged up by 0.06 percentage point to 3.12 %.

Year-to-date (Jan–Sep 2026) highlights • Cumulative revenue reached RMB 40.61 billion, a 3.11 % increase from the prior-year period. • Net profit attributable to shareholders slipped 1.07 % to RMB 1.48 billion, whereas core net profit (excluding non-recurring items) inched up 0.36 % to RMB 1.48 billion. • Operating activities used net cash of RMB 2.41 billion.

Balance-sheet snapshot (30 September 2026) • Total assets amounted to RMB 36.81 billion, up 0.35 % from end-2025. • Equity attributable to shareholders rose 4.66 % to RMB 19.41 billion.

The disclosed figures are unaudited and were published pursuant to Hong Kong Listing Rule 13.09 and Part XIVA of the Securities and Futures Ordinance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment